{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:04:59Z","timestamp":1791198299919,"version":"4.1.0"},"reference-count":141,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2004,5,1]],"date-time":"2004-05-01T00:00:00Z","timestamp":1083369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2004,5]]},"DOI":"10.1016\/j.pharmthera.2004.01.003","type":"journal-article","created":{"date-parts":[[2004,5,30]],"date-time":"2004-05-30T20:56:15Z","timestamp":1085950575000},"page":"139-153","source":"Crossref","is-referenced-by-count":113,"title":["Prostacyclin and its analogues in the treatment of pulmonary hypertension"],"prefix":"10.1016","volume":"102","author":[{"given":"Horst","family":"Olschewski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Schermuly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.Ardeschir","family":"Ghofrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Enke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Olschewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Seeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2004.01.003_BIB1","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1378\/chest.122.1.378","article-title":"Severe erythroderma as a complication of continuous epoprostenol therapy","volume":"122","author":"Ahearn","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB2","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1164\/ajrccm\/148.2.519","article-title":"Circulating immunoreactive endothelin-1 in children with pulmonary hypertension. Association with acute hypoxic pulmonary vasoreactivity","volume":"148","author":"Allen","year":"1993","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB3","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/S0003-4975(96)00542-5","article-title":"Rebound pulmonary hypertension after inhalation of nitric oxide","volume":"62","author":"Atz","year":"1996","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB4","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","article-title":"Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial","volume":"132","author":"Badesch","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB5","doi-asserted-by":"crossref","first-page":"409","DOI":"10.7326\/0003-4819-121-6-199409150-00003","article-title":"Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin","volume":"121","author":"Barst","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB6","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group","volume":"334","author":"Barst","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB7","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1161\/01.CIR.99.9.1197","article-title":"Vasodilator therapy for primary pulmonary hypertension in children","volume":"99","author":"Barst","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB8","series-title":"1998 World Symposium Primary Pulmonary Hypertension","article-title":"Medical treatment of pulmonary hypertension with prostacyclin","author":"Brundage","year":"1998"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB9","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1378\/chest.109.6.1545","article-title":"Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension: an ambulatory delivery system and initial clinical tests","volume":"109","author":"Channick","year":"1996","journal-title":"Chest"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB10","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1056\/NEJM199207093270202","article-title":"An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension","volume":"327","author":"Christman","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB11","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0014-2999(98)00549-4","article-title":"Evidence that Ca2+-activated K+ channels play a major role in mediating the vascular effects of iloprost and cicaprost","volume":"356","author":"Clapp","year":"1998","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB12","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1165\/ajrcmb.26.2.4695","article-title":"Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery","volume":"26","author":"Clapp","year":"2002","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB13","first-page":"205","article-title":"International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes","volume":"46","author":"Coleman","year":"1994","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB14","doi-asserted-by":"crossref","first-page":"67A","DOI":"10.1016\/S0002-9149(99)80386-5","article-title":"Role of prostacyclin in the treatment of primary pulmonary hypertension","volume":"75","author":"Cremona","year":"1995","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB15","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1182\/blood.V78.2.382.382","article-title":"The stable prostacyclin analog, iloprost, and prostaglandin E1 inhibit monocyte procoagulant activity in vitro","volume":"78","author":"Crutchley","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB16","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1161\/01.ATV.13.7.1082","article-title":"Effects of prostacyclin analogues on human endothelial cell tissue factor expression","volume":"13","author":"Crutchley","year":"1993","journal-title":"Arterioscler Thromb"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB17","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1111\/j.1651-2227.1997.tb14909.x","article-title":"Life-threatening effects of discontinuing inhaled nitric oxide in children","volume":"86","author":"Cueto","year":"1997","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB18","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0014-5793(98)01407-0","article-title":"Prostaglandins prevent inducible nitric oxide synthase protein expression by inhibiting nuclear factor-kappaB activation in J774 macrophages","volume":"440","author":"D'Acquisto","year":"1998","journal-title":"FEBS Lett"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB19","doi-asserted-by":"crossref","first-page":"343","DOI":"10.7326\/0003-4819-115-5-343","article-title":"Survival in patients with primary pulmonary hypertension. Results from a national prospective registry","volume":"115","author":"D'Alonzo","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB20","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1164\/ajrccm.165.3.2104059","article-title":"ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells","volume":"165","author":"Davie","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB21","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1183\/09031936.98.12040932","article-title":"Endotracheal instillation of prostacyclin in preterm infants with persistent pulmonary hypertension","volume":"12","author":"De Jaegere","year":"1998","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB22","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0952-3278(97)90531-7","article-title":"Differential effects of cyclo-oxygenase pathway metabolites on cytokine production by T lymphocytes","volume":"56","author":"Della","year":"1997","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB23","first-page":"135","article-title":"Cytokine production in scleroderma patients: effects of therapy with either iloprost or nifedipine","volume":"15","author":"Della","year":"1997","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB24","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s001340050973","article-title":"Inhaled nitric oxide in acute lung injury and acute respiratory distress syndrome. Inability to translate physiologic benefit to clinical outcome benefit in adult clinical trials","volume":"25","author":"Dellinger","year":"1999","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB25","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/00003246-199801000-00011","article-title":"Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial. Inhaled Nitric Oxide in ARDS Study Group","volume":"26","author":"Dellinger","year":"1998","journal-title":"Crit Care Med"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB26","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/sj.bjp.0700912","article-title":"Role of potassium channels and nitric oxide in the effects of iloprost and prostaglandin E1 on hypoxic vasoconstriction in the isolated perfused lung of the rat","volume":"120","author":"Dumas","year":"1997","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB27","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1152\/japplphysiol.00829.2001","article-title":"Hypoxia-induced pulmonary endothelin-1 expression is unaltered by nitric oxide","volume":"92","author":"Earley","year":"2002","journal-title":"J Appl Physiol"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB28","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1007\/BF02044111","article-title":"Aerosolized prostacyclin and inhaled nitric oxide in septic shock\u2014different effects on splanchnic oxygenation?","volume":"22","author":"Eichelbronner","year":"1996","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB29","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/s003920070150","article-title":"Iloprost as inhalational and intravenous long-term treatment of patients with primary pulmonary hypertension. Register of the Berlin Study Group for Pulmonary Hypertension","volume":"89","author":"Ewert","year":"2000","journal-title":"Z Kardiol"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB30","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1161\/01.CIR.96.9.2782","article-title":"Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension","volume":"96","author":"Friedman","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB31","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1054-3589(08)61102-3","article-title":"Inhaled nitric oxide, clinical rationale and applications","volume":"34","author":"Frostell","year":"1995","journal-title":"Adv Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB32","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1161\/01.RES.85.11.985","article-title":"Distinct role of cAMP and cGMP in the cell cycle control of vascular smooth muscle cells: cGMP delays cell cycle transition through suppression of cyclin D1 and cyclin-dependent kinase 4 activation","volume":"85","author":"Fukumoto","year":"1999","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB33","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0735-1097(02)01786-2","article-title":"Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial","volume":"39","author":"Galie","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB34","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1183\/09031936.01.17100140","article-title":"Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension","volume":"17","author":"Gessler","year":"2001","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB37","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1097\/00003246-200211000-00014","article-title":"Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension","volume":"30","author":"Ghofrani","year":"2002","journal-title":"Crit Care Med"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB35","doi-asserted-by":"crossref","first-page":"515","DOI":"10.7326\/0003-4819-136-7-200204020-00008","article-title":"Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension","volume":"136","author":"Ghofrani","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB36","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(02)11024-5","article-title":"Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial","volume":"360","author":"Ghofrani","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB38","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1164\/rccm.200210-1157BC","article-title":"Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension","volume":"167","author":"Ghofrani","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB39","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1056\/NEJM199306173282402","article-title":"Expression of endothelin-1 in the lungs of patients with pulmonary hypertension","volume":"328","author":"Giaid","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB40","doi-asserted-by":"crossref","first-page":"26879","DOI":"10.1074\/jbc.272.43.26879","article-title":"Cyclic AMP-mediated inhibition of angiotensin II-induced protein synthesis is associated with suppression of tyrosine phosphorylation signaling in vascular smooth muscle cells","volume":"272","author":"Giasson","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB41","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/0002-8703(85)90013-4","article-title":"A comparison of the acute hemodynamic effects of prostacyclin and hydralazine in primary pulmonary hypertension","volume":"110","author":"Groves","year":"1985","journal-title":"Am Heart J"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB42","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1023\/A:1005385302064","article-title":"Myosin light chain phosphatase: subunit composition, interactions and regulation","volume":"19","author":"Hartshorne","year":"1998","journal-title":"J Muscle Res Cell Motil"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB43","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1161\/01.CIR.86.3.896","article-title":"Adenosine infusion for the reversal of pulmonary vasoconstriction in biventricular failure. A good test but a poor therapy","volume":"86","author":"Haywood","year":"1992","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB44","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0140-6736(84)91452-1","article-title":"Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin)","volume":"1","author":"Higenbottam","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB45","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1136\/hrt.70.4.366","article-title":"Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension","volume":"70","author":"Higenbottam","year":"1993","journal-title":"Br Heart J"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB47","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1136\/hrt.79.2.175","article-title":"Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost","volume":"79","author":"Higenbottam","year":"1998","journal-title":"Heart"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB46","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1136\/hrt.80.2.151","article-title":"Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension","volume":"80","author":"Higenbottam","year":"1998","journal-title":"Heart"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB48","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/0090-6980(92)90138-J","article-title":"Pharmacokinetics of iloprost and cicaprost in mice","volume":"44","author":"Hildebrand","year":"1992","journal-title":"Prostaglandins"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB49","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0090-6980(89)90062-2","article-title":"Pharmacokinetics of 3H-cicaprost in healthy volunteers","volume":"37","author":"Hildebrand","year":"1989","journal-title":"Prostaglandins"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB50","first-page":"430","article-title":"Pharmacokinetics of iloprost in patients with hepatic dysfunction","volume":"28","author":"Hildebrand","year":"1990","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB52","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0735-1097(99)00494-5","article-title":"A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH Study Group","volume":"35","author":"Hoeper","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB51","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1056\/NEJM200006223422503","article-title":"Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue","volume":"342","author":"Hoeper","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB53","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1203\/00006450-199603000-00010","article-title":"Chronic intrauterine pulmonary hypertension alters endothelin receptor activity in the ovine fetal lung","volume":"39","author":"Ivy","year":"1996","journal-title":"Pediatr Res"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB54","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1172\/JCI119274","article-title":"Prolonged endothelin A receptor blockade attenuates chronic pulmonary hypertension in the ovine fetus","volume":"99","author":"Ivy","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB55","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1053\/pcad.2002.130041","article-title":"Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension","volume":"45","author":"Jeffery","year":"2002","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB56","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/j.1440-1681.1997.tb02730.x","article-title":"Prostanoid action on the human pulmonary vascular system","volume":"24","author":"Jones","year":"1997","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB57","first-page":"495","article-title":"Specific binding of the new stable epoprostenol analogue beraprost sodium to prostacyclin receptors on human and rat platelets","volume":"39","author":"Kajikawa","year":"1989","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB58","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/7426","article-title":"Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor","volume":"5","author":"Kennedy","year":"1999","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB59","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0022-3476(97)70124-0","article-title":"Randomized, multicenter trial of inhaled nitric oxide and high-frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newborn","volume":"131","author":"Kinsella","year":"1997","journal-title":"J Pediatr"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB60","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/sj.bjp.0701367","article-title":"Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells","volume":"122","author":"Kiriyama","year":"1997","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB61","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/BF00614197","article-title":"Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man","volume":"30","author":"Krause","year":"1986","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB62","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1097\/00007890-199904270-00001","article-title":"Portopulmonary hypertension and the liver transplant candidate","volume":"67","author":"Kuo","year":"1999","journal-title":"Transplantation"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB63","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1006\/jsre.1998.5312","article-title":"Prostaglandin I2 analogue, iloprost, down regulates mitogen-activated protein kinases of macrophages","volume":"76","author":"Lo","year":"1998","journal-title":"J Surg Res"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB64","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/j.1399-6576.1997.tb04639.x","article-title":"A retrospective analysis of nitric oxide inhalation in patients with severe acute lung injury in Sweden and Norway 1991-1994","volume":"41","author":"Luhr","year":"1997","journal-title":"Acta Anaesthesiol Scand"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB65","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1399-6576.1998.tb05131.x","article-title":"Pulmonary function in adult survivors of severe acute lung injury treated with inhaled nitric oxide","volume":"42","author":"Luhr","year":"1998","journal-title":"Acta Anaesthesiol Scand"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB66","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s001340050982","article-title":"Inhalation of nitric oxide in acute lung injury: results of a European multicentre study. The European Study Group of Inhaled Nitric Oxide","volume":"25","author":"Lundin","year":"1999","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB67","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1056\/NEJM199801293380501","article-title":"Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension","volume":"338","author":"McLaughlin","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB68","doi-asserted-by":"crossref","first-page":"740","DOI":"10.7326\/0003-4819-130-9-199905040-00014","article-title":"Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series","volume":"130","author":"McLaughlin","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB69","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1161\/01.CIR.0000029100.82385.58","article-title":"Survival in primary pulmonary hypertension: the impact of epoprostenol therapy","volume":"106","author":"McLaughlin","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB70","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/00005344-200302000-00019","article-title":"Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension","volume":"41","author":"McLaughlin","year":"2003","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB71","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0140-6736(95)92681-X","article-title":"Rebound pulmonary hypertension on withdrawal from inhaled nitric oxide","volume":"346","author":"Miller","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB72","first-page":"867","article-title":"General pharmacology of beraprost sodium. 2nd communication: effect on the autonomic, cardiovascular and gastrointestinal systems, and other effects","volume":"39","author":"Murata","year":"1989","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB73","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S0735-1097(99)00312-5","article-title":"Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension","volume":"34","author":"Nagaya","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB74","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0005-2760(95)00146-4","article-title":"Molecular mechanisms of diverse actions of prostanoid receptors","volume":"1259","author":"Negishi","year":"1995","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB75","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/36342","article-title":"The prostaglandin receptor EP4 triggers remodelling of the cardiovascular system at birth","volume":"390","author":"Nguyen","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1254\/jjp.47.1","article-title":"The in vitro and ex vivo antiplatelet effect of TRK-100, a stable prostacyclin analog, in several species","volume":"47","author":"Nishio","year":"1988","journal-title":"Jpn J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB77","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/S0140-6736(97)24019-5","article-title":"Orally active prostacyclin analogue in primary pulmonary hypertension","volume":"349","author":"Okano","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB78","doi-asserted-by":"crossref","first-page":"820","DOI":"10.7326\/0003-4819-124-9-199605010-00006","article-title":"Aerosolized prostacyclin and iloprost in severe pulmonary hypertension","volume":"124","author":"Olschewski","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB79","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s001340050628","article-title":"Recovery from circulatory shock in severe primary pulmonary hypertension (PPH) with aerosolization of iloprost","volume":"24","author":"Olschewski","year":"1998","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB80","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1164\/ajrccm.160.2.9810008","article-title":"Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis","volume":"160","author":"Olschewski","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB81","doi-asserted-by":"crossref","first-page":"435","DOI":"10.7326\/0003-4819-132-6-200003210-00003","article-title":"Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group","volume":"132","author":"Olschewski","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB83","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1067\/mlc.2001.119329","article-title":"Physiologic basis for the treatment of pulmonary hypertension","volume":"138","author":"Olschewski","year":"2001","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB82","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1067\/mlc.2001.119285","article-title":"Cellular pathophysiology and therapy of pulmonary hypertension","volume":"138","author":"Olschewski","year":"2001","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB85","first-page":"A1151","article-title":"Iloprost activates iberiotoxin-sensitive potassium current, hyperpolarizes resting membrane potential and decreases cytosolic calcium in fetal and adult pulmonary smooth muscle cells","volume":"106","author":"Olschewski","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB84","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa020204","article-title":"Inhaled iloprost for severe pulmonary hypertension","volume":"347","author":"Olschewski","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB86","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1164\/ajrccm.155.3.9117037","article-title":"HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study","volume":"155","author":"Opravil","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB87","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/0140-6736(91)92033-X","article-title":"Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension","volume":"338","author":"Pepke-Zaba","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB88","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1161\/01.CIR.89.6.2722","article-title":"Pulmonary hypertension in patients with human immunodeficiency virus infection. Comparison with primary pulmonary hypertension","volume":"89","author":"Petitpretz","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB89","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/S0024-3205(98)00093-9","article-title":"Prostanoid receptor heterogeneity through alternative mRNA splicing","volume":"62","author":"Pierce","year":"1998","journal-title":"Life Sci"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB90","doi-asserted-by":"crossref","first-page":"35944","DOI":"10.1074\/jbc.274.50.35944","article-title":"Activation of FP prostanoid receptor isoforms leads to Rho-mediated changes in cell morphology and in the cell cytoskeleton","volume":"274","author":"Pierce","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB91","doi-asserted-by":"crossref","first-page":"2S","DOI":"10.1378\/chest.105.2_Supplement.2S","article-title":"Histopathology of primary pulmonary hypertension","volume":"105","author":"Pietra","year":"1994","journal-title":"Chest"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB92","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/00007890-199802270-00001","article-title":"Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension","volume":"65","author":"Plotkin","year":"1998","journal-title":"Transplantation"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB93","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1164\/ajrccm.157.6.9609017","article-title":"Cardiopulmonary effects of aerosolized prostaglandin E1 and nitric oxide inhalation in patients with acute respiratory distress syndrome","volume":"157","author":"Putensen","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB94","unstructured":"Rich, S. (1998). Primary pulmonary hypertension. Available at: http:\/\/www.who.int\/ncd\/cvd\/pph.html."},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB95","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1161\/01.CIR.76.1.135","article-title":"High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy","volume":"76","author":"Rich","year":"1987","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB96","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1056\/NEJM199207093270203","article-title":"The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension","volume":"327","author":"Rich","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB97","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1165\/ajrcmb\/3.4.301","article-title":"Iloprost inhibits neutrophil-induced lung injury and neutrophil adherence to endothelial monolayers","volume":"3","author":"Riva","year":"1990","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB98","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/0140-6736(92)92686-A","article-title":"Inhaled nitric oxide in persistent pulmonary hypertension of the newborn","volume":"340","author":"Roberts","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB99","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1056\/NEJM199702273360902","article-title":"Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. The Inhaled Nitric Oxide Study Group","volume":"336","author":"Roberts","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB100","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1160\/TH03-03-0173","article-title":"Increased neutrophil mediator release in patients with pulmonary hypertension\u2014suppression by inhaled iloprost","volume":"90","author":"Rose","year":"2003","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB101","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0022-3476(05)81552-5","article-title":"Elevated immunoreactive endothelin-1 levels in newborn infants with persistent pulmonary hypertension","volume":"123","author":"Rosenberg","year":"1993","journal-title":"J Pediatr"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB102","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1161\/01.CIR.99.14.1858","article-title":"Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects","volume":"99","author":"Rosenzweig","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB103","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1378\/chest.120.5.1562","article-title":"Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension","volume":"120","author":"Rubens","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB104","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/0002-8703(80)90246-X","article-title":"Primary pulmonary hypertension: new approaches to therapy","volume":"100","author":"Rubin","year":"1980","journal-title":"Am Heart J"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB105","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1056\/NEJM198001103020201","article-title":"Oral hydralazine therapy for primary pulmonary hypertension","volume":"302","author":"Rubin","year":"1980","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB106","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1161\/01.CIR.66.2.334","article-title":"Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension","volume":"66","author":"Rubin","year":"1982","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB107","doi-asserted-by":"crossref","first-page":"485","DOI":"10.7326\/0003-4819-112-7-485","article-title":"Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial","volume":"112","author":"Rubin","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB108","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB109","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0002-9149(96)90408-7","article-title":"Short-term hemodynamic effect of a new oral PGI2 analogue, beraprost, in primary and secondary pulmonary hypertension","volume":"78","author":"Saji","year":"1996","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB110","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1161\/01.CIR.89.4.1733","article-title":"Survival in primary pulmonary hypertension. Validation of a prognostic equation","volume":"89","author":"Sandoval","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB111","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1164\/ajrccm.160.5.9901102","article-title":"Low-dose systemic phosphodiesterase inhibitors amplify the pulmonary vasodilatory response to inhaled prostacyclin in experimental pulmonary hypertension","volume":"160","author":"Schermuly","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB112","first-page":"512","article-title":"Subthreshold doses of specific phosphodiesterase type 3 and 4 inhibitors enhance the pulmonary vasodilatory response to nebulized prostacyclin with improvement in gas exchange","volume":"292","author":"Schermuly","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB113","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1164\/ajrccm.164.9.2105060","article-title":"Coaerosolization of phosphodiesterase inhibitors markedly enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension. maintenance of lung selectivity","volume":"164","author":"Schermuly","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB114","doi-asserted-by":"crossref","first-page":"L1361","DOI":"10.1152\/ajplung.2001.281.6.L1361","article-title":"Combination of nonspecific PDE inhibitors with inhaled prostacyclin in experimental pulmonary hypertension","volume":"281","author":"Schermuly","year":"2001","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB115","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1183\/09031936.03.00093802","article-title":"Zardaverine and aerosolised iloprost in a model of acute respiratory failure","volume":"22","author":"Schermuly","year":"2003","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB116","first-page":"63","article-title":"Roles of vasodilatory prostaglandins in mitogenesis of vascular smooth muscle cells","volume":"48","author":"Schror","year":"1997","journal-title":"Agents Actions Suppl"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB117","doi-asserted-by":"crossref","first-page":"C1203","DOI":"10.1152\/ajpcell.1996.271.4.C1203","article-title":"Iloprost activates KCa channels of vascular smooth muscle cells: role of cAMP-dependent protein kinase","volume":"271","author":"Schubert","year":"1996","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB118","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0735-1097(97)00187-3","article-title":"Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion","volume":"30","author":"Shapiro","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB119","doi-asserted-by":"crossref","first-page":"195S","DOI":"10.1378\/chest.114.3_Supplement.195S","article-title":"Primary pulmonary hypertension associated with the use of fenfluramine derivatives","volume":"114","author":"Simonneau","year":"1998","journal-title":"Chest"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB120","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","article-title":"Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. A double-blind, randomized, placebo-controlled trial","volume":"165","author":"Simonneau","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB121","first-page":"92","article-title":"Antimitotic actions of vasodilatory prostaglandins\u2014clinical aspects","volume":"48","author":"Sinzinger","year":"1997","journal-title":"Agents Actions Suppl"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB122","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0735-1097(02)02012-0","article-title":"Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival","volume":"40","author":"Sitbon","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB123","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1021\/jm00153a001","article-title":"Synthesis of a new chemically and metabolically stable prostacyclin analogue with high and long-lasting oral activity","volume":"29","author":"Skuballa","year":"1986","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB124","first-page":"1263","article-title":"Inhaled nitric oxide used as a bridge to heart-lung transplantation in a patient with end-stage pulmonary hypertension","volume":"151","author":"Snell","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB125","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1378\/chest.100.5.1268","article-title":"Primary pulmonary hypertension in HIV infection","volume":"100","author":"Speich","year":"1991","journal-title":"Chest"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB126","first-page":"663","article-title":"Regression of HIV-associated pulmonary arterial hypertension and long-term survival during antiretroviral therapy","volume":"131","author":"Speich","year":"2001","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB127","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0090-6980(86)90228-5","article-title":"Pharmacological profile of a novel carbacyclin derivative with high metabolic stability and oral activity in the rat","volume":"31","author":"Sturzebecher","year":"1986","journal-title":"Prostaglandins"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB128","first-page":"L366","article-title":"ETA and ETB receptors cooperate in DNA synthesis via opposing regulations of cAMP in human lung cell line","volume":"271","author":"Takimoto","year":"1996","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB129","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1164\/ajrccm.159.6.9804054","article-title":"Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension","volume":"159","author":"Tuder","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB130","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0021-9150(97)00116-0","article-title":"G1 phase arrest of human smooth muscle cells by heparin, IL-4 and cAMP is linked to repression of cyclin D1 and cdk2","volume":"133","author":"Vadiveloo","year":"1997","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB131","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/sj.bjp.0702393","article-title":"Prostanoid receptors involved in the relaxation of human pulmonary vessels","volume":"126","author":"Walch","year":"1999","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB132","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/0140-6736(93)92004-D","article-title":"Aerosolised prostacyclin in adult respiratory distress syndrome","volume":"342","author":"Walmrath","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB133","first-page":"724","article-title":"Effects of aerosolized prostacyclin in severe pneumonia. Impact of fibrosis","volume":"151","author":"Walmrath","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB134","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1164\/ajrccm.153.3.8630585","article-title":"Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome","volume":"153","author":"Walmrath","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB135","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0140-6736(80)91522-6","article-title":"Prostacyclin and prostaglandin E1 for severe idiopathic pulmonary artery hypertension","volume":"1","author":"Watkins","year":"1980","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB136","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1161\/01.CIR.102.25.3130","article-title":"Prostacyclin analogues differentially inhibit growth of distal and proximal human pulmonary artery smooth muscle cells","volume":"102","author":"Wharton","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB137","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/0090-6980(76)90126-X","article-title":"The chemical structure of prostaglandin \u00d7 (prostacyclin)","volume":"12","author":"Whittaker","year":"1976","journal-title":"Prostaglandins"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB138","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1161\/hc3601.096826","article-title":"Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension","volume":"104","author":"Wilkens","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB139","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1164\/ajrccm.157.1.9704003","article-title":"5-Lipoxygenase and 5-lipoxygenase activating protein (FLAP) immunoreactivity in lungs from patients with primary pulmonary hypertension","volume":"157","author":"Wright","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB140","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0014-5793(96)00160-3","article-title":"Peroxynitrite formed by simultaneous generation of nitric oxide and superoxide selectively inhibits bovine aortic prostacyclin synthase","volume":"382","author":"Zou","year":"1996","journal-title":"FEBS Lett"},{"key":"10.1016\/j.pharmthera.2004.01.003_BIB141","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1164\/ajrccm.154.6.8970353","article-title":"Inhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndrome","volume":"154","author":"Zwissler","year":"1996","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725804000373?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725804000373?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T09:14:49Z","timestamp":1585818889000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725804000373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5]]},"references-count":141,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,5]]}},"alternative-id":["S0163725804000373"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2004.01.003","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2004,5]]}}}